Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain
Elranatamab is a cost-effective treatment versus PCT and dominant over teclistamab for the treatment of adult patients with TCE-RRMM in the Spanish setting.
Authors
- Julia Llinares
- Cristina Encinas (ORCID: https://orcid.org/0000-0002-9001-9754)
- Joaquín Martínez‐López (ORCID: https://orcid.org/0000-0001-7908-0063)
- Patrick Hlavacek (ORCID: https://orcid.org/0000-0002-4752-3218)
- David Carcedo (ORCID: https://orcid.org/0000-0002-2809-7399)
- Sofía Toribio-Castelló (ORCID: https://orcid.org/0000-0001-8879-3057)
- Jordi Asís-Montalt
- Virginia Lozano
Institutions
- Pfizer (United States) (US)
- Saint Louis University (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitario 12 De Octubre (ES)
- Elytt Energy (Spain) (ES)
- Hygeia Hospital (GR)
- Pfizer (Spain) (ES)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1007/s40487-025-00333-7
- Citations
- 5
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.85